Proteoglycans in health and disease: The multiple roles of syndecan shedding

FEBS Journal

Volumn 277, Issue 19, 2010, Pages 3876-3889

  Manon Jensen, Tina ^b   Itoh, Yoshifumi ^b   Couchman, John R ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

cell adhesion; cell migration; glycosaminoglycan; growth factor; heparan sulfate; metzincin; proteinase; proteoglycan; receptors; signaling

Indexed keywords

GROWTH FACTOR; MATRIX PROTEIN; POLYPEPTIDE; PROTEOGLYCAN; SYNDECAN; BETA GLUCURONIDASE; HEPARANASE; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

AUTOCRINE EFFECT; CANCER CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SPREADING; CELL SURFACE; CELL SURVIVAL; COMPETITIVE INHIBITION; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; HEALTH; HUMAN; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; REGULATORY MECHANISM; SHORT SURVEY; WOUND HEALING; ANIMAL; CELL DIVISION; CELL MOTION; DISEASE COURSE; MAMMAL; METABOLISM; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE;

ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; CELL MOVEMENT; DISEASE PROGRESSION; GLUCURONIDASE; HUMANS; MAMMALS; MATRIX METALLOPROTEINASES; NEOPLASMS; PROTEOGLYCANS; REFERENCE VALUES; SYNDECANS; TISSUE INHIBITOR OF METALLOPROTEINASES; WOUND HEALING;

EID: 77956646126     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07798.x     Document Type: Short Survey

References (124)

1. Rawson JM, Dimitroff B, Johnson KG, Rawson JM, Ge X, Van Vactor D Selleck SB (2005) The heparan sulfate proteoglycans Dally-like and Syndecan have distinct functions in axon guidance and visual-system assembly in Drosophila. Curr Biol 15, 833 838.
2. Rhiner C, Gysi S, Frohli E, Hengartner MO Hajnal A (2005) Syndecan regulates cell migration and axon guidance in C. elegans. Development 132, 4621 4633.
3. Kim CW, Goldberger OA, Gallo RL Bernfield M (1994) Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol Biol Cell 5, 797 805.
4. Morgan MR, Humphries MJ Bass MD (2007) Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol 8, 957 969.
5. Okina E, Manon-Jensen T, Whiteford Jr. Couchman Jr. (2009) Syndecan proteoglycan contributions to cytoskeletal organization and contractility. Scand J Med Sci Sports 19, 479 489.
6. Xian X, Gopal S Couchman Jr. (2010) Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue Res 339, 31 46.
7. Granés F, Urena JM, Rocamora N Vilaró S (2000) Ezrin links syndecan-2 to the cytoskeleton. J Cell Sci 113, 1267 1276.
8. Couchman Jr. (2003) Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol 4, 926 937.
9. Oh ES, Couchman Jr. Woods A (1997) Serine phosphorylation of syndecan-2 proteoglycan cytoplasmic domain. Arch Biochem Biophys 1, 67 74.
10. Baciu PC, Saoncella S, Lee SH, Denhez F, Leuthardt D Goetinck PF (2000) Syndesmos, a protein that interacts with the cytoplasmic domain of syndecan-4, mediates cell spreading and actin cytoskeletal organization. J Cell Sci 113, 315 324.
11. Choi S, Lee E, Kwon S, Park H, Yi JY, Kim S, Han IO, Yun Y Oh ES (2005) Transmembrane domain-induced oligomerization is crucial for the functions of syndecan-2 and syndecan-4. J Biol Chem 280, 42573 42579.
12. Dews IC Mackenzie KR (2007) Transmembrane domains of the syndecan family of growth factor coreceptors display a hierarchy of homotypic and heterotypic interactions. Proc Natl Acad Sci USA 104, 20782 20787.
13. Bishop Jr. Schuksz M Esko JD (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030 1037.
14. Nadanaka S Kitagawa H (2008) Heparan sulphate biosynthesis and disease. J Biochem 144, 7 14.
15. Steinfeld R, Van Den Berghe H David G (1996) Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican. J Cell Biol 133, 405 416.
16. Brown MS, Ye J, Rawson RB Goldstein JL (2000) Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100, 391 398.
17. Schulz JG, Annaert W, Vandekerckhove J, Zimmermann P, De Strooper B David G (2003) Syndecan 3 intramembrane proteolysis is presenilin/gamma-secretase- dependent and modulates cytosolic signaling. J Biol Chem 278, 48651 48657.
18. Iozzo RV Schaefer L (2010) Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277, 3864 3875.
19. Visse R Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92, 827 839.
20. Cho NH, Shim HS, Rha SY, Kang SH, Hong SH, Choi YD, Hong SJ Cho SH (2003) Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol 44, 560 566.
21. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R Murray GI (2004) Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 10, 8229 8234.
22. Deryugina EI Quigley JP (2005) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25, 9 34.
23. Leco KJ, Khokha R, Pavloff N, Hawkes SP Edwards DR (1994) Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 269, 9352 9360.
24. Nagase H, Visse R Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69, 562 573.
25. Yu WH, Yu S, Meng Q, Brew K Woessner JF (2000) TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 275, 31226 31232.
26. Fitzgerald ML, Wang Z, Park PW, Murphy G Bernfield M (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148, 811 824.
27. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Stephens PE, Shelley C, Hutton M, Knäuper V et al. (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435, 39 44.
28. Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, Knäuper V, Docherty AJ Murphy G (2000) The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 473, 275 279.
29. Loechel F, Fox JW, Murphy G, Albrechtsen R Wewer UM (2000) ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 278, 511 515.
30. Kashiwagi M, Tortorella M, Nagase H Brew K (2001) TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAMTS-4) and aggrecanase 2 (ADAMTS-5). J Biol Chem 276, 12501 12504.
31. Rapti M, Atkinson SJ, Lee MH, Trim A, Moss M Murphy G (2008) The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. Biochem J 411, 433 439.
32. Roderfeld M, Graf J, Giese B, Salguero-Palacios R, Tschuschner A, Müller-Newen G Roeb E (2007) Latent MMP-9 is bound to TIMP-1 before secretion. Biol Chem 388, 1227 1234.
33. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E Seiki M (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370, 61 65.
34. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA Goldberg GI (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270, 5331 5338.
35. Itoh Y, Ito N, Nagase H Seiki M (2008) The second dimer interface of MT1-MMP, the transmembrane domain, is essential for ProMMP-2 activation on the cell surface. J Biol Chem 283, 13053 13062.
36. Jalkanen M, Rapraeger A, Saunders S Bernfield MJ (1987) Cell surface proteoglycan of mouse mammary epithelial cells is shed by cleavage of its matrix-binding ectodomain from its membrane-associated domain. Cell Biol 105, 3087 3096.
37. Kainulainen V, Wang H, Schick C Bernfield M (1998) Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J Biol Chem 273, 11563 11569.
38. Spring J, Paine-Saunders SE, Hynes RO Bernfield M (1994) Drosophila syndecan: conservation of a cell-surface heparan sulfate proteoglycan. Proc Natl Acad Sci USA 91, 3334 3338.
39. Yanagishita M Hascall VC (1992) Cell surface heparan sulfate proteoglycans. J Biol Chem 267, 9451 9454.
40. Li Q, Park PW, Wilson CL Parks WC (2002) Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111, 635 646.
41. Brule S, Charnaux N, Sutton A, Ledoux D, Chaigneau T, Saffar L Gattegno L (2006) The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 16, 488 501.
42. Fears CY, Gladson CL Woods A (2006) Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. J Biol Chem 281, 14533 14536.
43. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M Sato H (2003) Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 278, 40764 40770.
44. Schmidt A, Echtermeyer F, Alozie A, Brands K Buddecke E (2005) Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds. J Biol Chem 280, 34441 34446.
45. Wang Z, Götte M, Bernfield M Reizes O (2005) Constitutive and accelerated shedding of murine syndecan-1 is mediated by cleavage of its core protein at a specific juxtamembrane site. Biochemistry 44, 12355 12361.
46. Edwards DR, Handsley MM Pennington CJ (2008) The ADAM metalloproteinases. Mol Aspects Med 29, 258 289.
47. Pruessmeyer J, Martin C, Hess FM, Schwarz N, Schmidt S, Kogel T, Hoettecke N, Schmidt B, Sechi A, Uhlig S et al. (2010) A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells. J Biol Chem 285, 555 564.
48. Iba K, Albrechtsen R, Gilpin B, Fröhlich C, Loechel F, Zolkiewska A, Ishiguro K, Kojima T, Liu W, Langford JK et al. (2000) The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J Cell Biol 149, 1143 1156.
49. Sørensen HP, Vivès RR, Manetopoulos C, Albrechtsen R, Lydolph MC, Jacobsen J, Couchman Jr. Wewer UM (2008) Heparan sulfate regulates ADAM12 through a molecular switch mechanism. J Biol Chem 283, 31920 31932.
50. Porter S, Clark IM, Kevorkian L Edwards DR (2005) The ADAMTS metalloproteinases. Biochem J 386, 15 27.
51. Gao G, Plaas A, Thompson VP, Jin S, Zuo F Sandy JD (2004) ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J Biol Chem 279, 10042 10051.
52. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA, Decicco CP, Wynn R et al. (1999) Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 284, 1664 1666.
53. Echtermeyer F, Bertrand J, Dreier R, Meinecke I, Neugebauer K, Fuerst M, Lee YJ, Song YW, Herzog C, Theilmeier G et al. (2009) Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat Med 15, 1072 1076.
54. Rodríguez-Manzaneque JC, Carpizo D, Plaza-Calonge Mdel C, Torres-Collado AX, Thai SN, Simons M, Horowitz A Iruela-Arispe ML (2008) Cleavage of syndecan-4 by ADAMTS1 provokes defects in adhesion. Int J Biochem Cell Biol 41, 800 810.
55. Subramanian SV, Fitzgerald ML Bernfield M (1997) Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 272, 14713 14720.
56. Charnaux N, Brule S, Chaigneau T, Saffar L, Sutton A, Hamon M, Prost C, Lievre N, Vita C Gattegno L (2005) RANTES (CCL5) induces a CCR5-dependent accelerated shedding of syndecan-1 (CD138) and syndecan-4 from HeLa cells and forms complexes with the shed ectodomains of these proteoglycans as well as with those of CD44. Glycobiology 15, 119 130.
57. Chen Y, Hayashida A, Bennett AE, Hollingshead SK Park PW (2007) Streptococcus pneumoniae sheds syndecan-1 ectodomains through ZmpC, a metalloproteinase virulence factor. J Biol Chem 282, 159 167.
58. Park PW, Foster TJ, Nishi E, Duncan SJ, Klagsbrun M Chen Y (2004) Activation of syndecan-1 ectodomain shedding by Staphylococcus aureus alpha-toxin and beta-toxin. J Biol Chem 279, 251 258.
59. Wang JB, Guan J, Shen J, Zhou L, Zhang YJ, Si YF, Yang L, Jian XH Sheng Y (2009) Insulin increases shedding of syndecan-1 in the serum of patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 86, 83 88.
60. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD Jr. , Sawyer J, Li JP, Zcharia E, Vlodavsky I et al. (2007) Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282, 13326 13333.
61. Andrian E, Grenier D Rouabhia M (2005) Porphyromonas gingivalis lipopolysaccharide induces shedding of syndecan-1 expressed by gingival epithelial cells. J Cell Physiol 204, 178 183.
62. Park PW, Pier GB, Hinkes MT Bernfield M (2001) Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 411, 98 102.
63. Popova TG, Millis B, Bradburne C, Nazarenko S, Bailey C, Chandhoke V Popov SG (2006) Acceleration of epithelial cell syndecan-1 shedding by anthrax hemolytic virulence factors. BMC Microbiol 6, 8.
64. Chung MC, Popova TG, Millis BA, Mukherjee DV, Zhou W, Liotta LA, Petricoin EF, Chandhoke V, Bailey C Popov SG (2006) Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors. J Biol Chem 281, 31408 31418.
65. Kalia M, Chandra V, Rahman SA, Sehgal D Jameel S (2009) Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection. J Virol 83, 12714 12724.
66. Horowitz A Simons M (1998) Regulation of syndecan-4 phosphorylation in vivo. J Biol Chem 273, 10914 10918.
67. Ott VL Rapraeger AC (1998) Tyrosine phosphorylation of syndecan-1 and -4 cytoplasmic domains in adherent B82 fibroblasts. J Biol Chem 273, 35291 35298.
68. Reiland J, Ott VL, Lebakken CS, Yeaman C, McCarthy J Rapraeger AC (1996) Pervanadate activation of intracellular kinases leads to tyrosine phosphorylation and shedding of syndecan-1. Biochem J 319, 39 47.
69. Hayashida K, Stahl PD Park PW (2008) Syndecan-1 ectodomain shedding is regulated by the small GTPase Rab5. J Biol Chem 283, 35435 35444.
70. Martin P Leibovich SJ (2005) Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 15, 599 607.
71. Cizmeci-Smith G, Langan E, Youkey J, Showalter LJ Carey DJ (1997) Syndecan-4 is a primary-response gene induced by basic fibroblast growth factor and arterial injury in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17, 172 180.
72. Gallo R, Kim C, Kokenyesi R, Adzick NS Bernfield M (1996) Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin. J Invest Dermatol 107, 676 683.
73. Lusis AJ (2000) Atherosclerosis. Nature 407, 233 241.
74. Houston M, Julien MA, Parthasarathy S Chaikof EL (2005) Oxidized linoleic acid regulates expression and shedding of syndecan-4. Am J Physiol Cell Physiol 288, 458 466.
75. Seidel C, Ringdén O Remberger M (2003) Increased levels of syndecan-1 in serum during acute graft-versus-host disease. Transplantation 76, 423 426.
76. Zlotnik A Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12, 121 127.
77. Elenius K, Vainio S, Laato M, Salmivirta M, Thesleff I Jalkanen MJ (1991) Induced expression of syndecan in healing wounds. Cell Biol 114, 585 595.
78. Chen P, Abacherli LE, Nadler ST, Wang Y, Li Q Parks WC (2009) MMP7 shedding of syndecan-1 facilitates re-epithelialization by affecting alpha(2)beta(1) integrin activation. PLoS ONE 10, e6565.
79. Leppä S, Vleminckx K, Van Roy F Jalkanen M (1996) Syndecan-1 expression in mammary epithelial tumor cells is E-cadherin-dependent. J Cell Sci 109, 1393 1403. (Pubitemid 26190489)
80. Kato M, Saunders S, Nguyen H Bernfield M (1995) Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 6, 559 576.
81. Grushkin-Lerner LS Trinkaus-Randall V (1991) Localization of integrin and syndecan in vivo in a corneal epithelial abrasion and keratectomy. Curr Eye Res 10, 75 85.
82. Oksala O, Salo T, Tammi R, Häkkinen L, Jalkanen M, Inki P Larjava H (1995) Expression of proteoglycans and hyaluronan during wound healing. J Histochem Cytochem 43, 125 135.
83. Kliment CR, Englert JM, Gochuico BR, Yu G, Kaminski N, Rosas I Oury TD (2009) Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis. J Biol Chem 284, 3537 3545.
84. Elenius V, Götte M, Reizes O, Elenius K Bernfield M (2004) Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1. J Biol Chem 279, 41928 41935.
85. Jurjus RA, Liu Y, Pal-Ghosh S, Tadvalkar G Stepp MA (2008) Primary dermal fibroblasts derived from sdc-1 deficient mice migrate faster and have altered alphav integrin function. Wound Repair Regen 16, 649 660.
86. McGuire JK, Li Q Parks WC (2003) Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 162, 1831 1843.
87. Beauvais DM, Ell BJ, McWhorter AR Rapraeger AC (2009) Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 206, 691 705.
88. Whiteford Jr. Behrends V, Kirby H, Kusche-Gullberg M, Muramatsu T Couchman Jr. (2007) Syndecans promote integrin-mediated adhesion of mesenchymal cells in two distinct pathways. Exp Cell Res 313, 3902 3913.
89. Whiteford Jr. Couchman Jr. (2006) A conserved NXIP motif is required for cell adhesion properties of the syndecan-4 ectodomain. J Biol Chem 281, 32156 32163.
90. Beauvais DM, Burbach BJ Rapraeger AC (2004) The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol 167, 171 181.
91. McQuade KJ, Beauvais DM, Burbach BJ Rapraeger AC (2006) Syndecan-1 regulates alphavbeta5 integrin activity in B82L fibroblasts. J Cell Sci 119, 2445 2456.
92. Langford JK, Yang Y, Kieber-Emmons T Sanderson RD (2005) Identification of an invasion regulatory domain within the core protein of syndecan-1. J Biol Chem 280, 3467 3473.
93. Vuoriluoto K, Jokinen J, Kallio K, Salmivirta M, Heino J Ivaska J (2008) Syndecan-1 supports integrin alpha2beta1-mediated adhesion to collagen. Exp Cell Res 314, 3369 3381.
94. Theocharis AD, Skandalis SS, Tzanakakis GN Karamanos NK (2010) Proteoglycans in health and disease: novel roles for proteoglycan in malignancy and their pharmacological targeting. FEBS J 277, 3904 3923.
95. Yu WH Woessner JF (2000) Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). J Biol Chem 275, 4183 4191.
96. Munteanu SE, Ilic MZ Handley CJ (2002) Highly sulfated glycosaminoglycans inhibit aggrecanase degradation of aggrecan by bovine articular cartilage explant cultures. Matrix Biol 21, 429 440.
97. Yu WH Woessner JF (2001) Heparin-enhanced zymographic detection of matrilysin and collagenases. Anal Biochem 293, 38 42.
98. Munesue S, Yoshitomi Y, Kusano Y, Koyama Y, Nishiyama A, Nakanishi H, Miyazaki K, Ishimaru T, Miyaura S, Okayama M et al. (2007) A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 282, 28164 28174.
99. Troeberg L, Fushimi K, Scilabra SD, Nakamura H, Dive V, Thøgersen IB, Enghild JJ Nagase H (2009) The C-terminal domains of ADAMTS-4 and ADAMTS-5 promote association with N-TIMP-3. Matrix Biol 28, 463 469.
100. Safaiyan F, Kolset SO, Prydz K, Gottfridsson E, Lindahl U Salmivirta M (1999) Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate. J Biol Chem 274, 36267 36273.
101. Zhang L, Yang M, Yang D, Cavey G, Davidson P Gibson G (2010) Molecular interactions of MMP-13 C-terminal domain with chondrocyte proteins. Connect Tissue Res 51, 230 239.
102. Beauvais DM Rapraeger AC (2004) Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2, 3.
103. Joensuu H, Anttonen A, Eriksson M, Mäkitaro R, Alfthan H, Kinnula V Leppä S (2002) Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 62, 5210 5217.
104. Vassilakopoulos TP, Kyrtsonis MC, Papadogiannis A, Nadali G, Angelopoulou MK, Tzenou T, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Kalpadakis C et al. (2005) Serum levels of soluble syndecan-1 in Hodgkin's lymphoma. Anticancer Res 25, 4743 4746.
105. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB Wilson CS (2001) Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Modern Pathol 14, 1052 1058.
106. Lovell R, Dunn JA, Begum G, Barth NJ, Plant T, Moss PA, Drayson MT Pratt G (2005) Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. Br J Haematol 130, 542 548.
107. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A Borset M (2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95, 388 392.
108. Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, Kelsch R, Fischgräbe J, Smollich M, Rossi LH et al. (2009) Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 30, 397 407.
109. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J Sanderson RD (2002) Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100, 610 617.
110. Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B Sanderson RD (1997) Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol 99, 368 371.
111. Kato M, Wang H, Kainulainen V, Fitzgerald ML, Ledbetter S, Ornitz DM Bernfield M (1998) Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4, 691 697.
112. Ilan N, Elkin M Vlodavsky I (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38, 2018 2039. (Pubitemid 44397619)
113. Levy-Adam F, Feld S, Suss-Toby E, Vlodavsky I Ilan N (2008) Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS ONE 3, e2319.
114. Zcharia E, Jia J, Zhang X, Baraz L, Lindahl U, Peretz T, Vlodavsky I Li JP (2009) Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS ONE 4, e5181.
115. Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ et al. (2005) Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 105, 1303 1309.
116. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F et al. (2003) High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 63, 8749 8756.
117. Barash U, Cohen-Kapaln V, Dowek J, Sanderson RD, Ilan N Vlodavsky I (2010) Proteoglycans in health and disease: new concepts arising for heparanase function in tumour progression and metastasis. FEBS J 277, 3890 3903.
118. Purushothaman A, Chen L, Yang Y Sanderson RD (2008) Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 283, 32628 32636.
119. Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC Sanderson RD (2010) Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115, 2449 2457.
120. Hjertner O, Qvigstad G, Hjorth-Hansen H, Seidel C, Woodliff J, Epstein J, Waage A, Sundan A Börset M (2000) Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol 109, 815 822.
121. Sfiridaki A, Miyakis S, Tsirakis G, Alegakis A, Passam AM, Kandidaki E, Margioris AN Alexandrakis MG (2005) Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. Clin Chem Lab Med 43, 934 938.
122. Van de Broek I, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K, Van Camp B Van Riet I (2004) Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 18, 976 982.
123. Van Valckenborgh E, Croucher PI, De Raeve H, Carron C, De Leenheer E, Blacher S, Devy L, Noël A, De Bruyne E, Asosingh K et al. (2004) Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. Am J Pathol 165, 869 878.
124. Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378, 151 160.